bezafibrate has been researched along with Hyperlipidemia, Familial Combined in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanco-Colio, LM; Díaz, C; Egido, J; Hernández, G; Martín-Ventura, JL; Sol, JM | 1 |
| Avisar, I; Brook, JG; Wolfovitz, E | 1 |
| Abate, N; Bertolotti, M; Carulli, N; Concari, M; Guicciardi, ME; Loria, P; Pinetti, A | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Grover, S; Hamilton, VH; Lavoie, F; Perreault, S | 1 |
| Hayashi, K; Hiraga, T; Kajiyama, G; Katano, T; Kuga, Y; Kurushima, H; Nomura, K; Ohtani, H; Sakai-Ohta, K; Shingu, T; Tanaka, K; Toyota, Y; Yasunobu, Y | 1 |
| Coufal, Z; Urbánek, R | 1 |
| Boschetti, C; Cofrancesco, E; Cortellaro, F; Cortellaro, M; Mancini, M; Mariani, M; Paoletti, R | 1 |
| Aristegui, R; Civeira, F; Díaz, C; García-Otín, AL; Hernández, G; Masramon, X; Pocoví, M; Recalde, D; Sol, JM | 1 |
| Karhapää, P; Laakso, M; Uusitupa, M; Voutilainen, E | 1 |
| Cabrera, J; Campos, MM; Escobar Jiménez, F; Núñez, J; Orduña, R; Torres, E; Vílchez Joya, R | 1 |
1 review(s) available for bezafibrate and Hyperlipidemia, Familial Combined
| Article | Year |
|---|---|
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male | 1997 |
6 trial(s) available for bezafibrate and Hyperlipidemia, Familial Combined
| Article | Year |
|---|---|
Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
Topics: Adult; Antineoplastic Agents; Atorvastatin; Bezafibrate; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Endothelial Cells; Fas Ligand Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Membrane Glycoproteins; Mevalonic Acid; Middle Aged; Pyrroles; Terpenes; Time Factors; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha | 2004 |
Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Topics: Aged; Atorvastatin; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Male | 1997 |
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Trea
Topics: Adult; Aged; Bezafibrate; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Tissue Plasminogen Activator; Treatment Outcome | 2000 |
Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bezafibrate; Cholesterol; DNA; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Triglycerides | 2002 |
5 other study(ies) available for bezafibrate and Hyperlipidemia, Familial Combined
| Article | Year |
|---|---|
Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans.
Topics: Adult; Bezafibrate; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged | 1995 |
Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance.
Topics: Adult; Aged; Apolipoproteins B; Bezafibrate; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Female; Glucose Tolerance Test; Glycoproteins; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoprotein Lipase; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged | 1998 |
[Bezafibrate in the treatment of familial combined hyperlipidemia and its effect on certain parameters of lipid metabolism, particularly fibrinogen].
Topics: Adult; Bezafibrate; Female; Fibrinogen; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged | 1998 |
Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia.
Topics: Bezafibrate; Calorimetry, Indirect; Delayed-Action Preparations; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperlipidemia, Familial Combined; Insulin Resistance; Liver; Male; Middle Aged; Triglycerides | 1992 |
[Effects of bezafibrate in patients with combined hyperlipidemia].
Topics: Arteriosclerosis; Bezafibrate; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hyperlipidemia, Familial Combined; Male; Triglycerides | 1986 |